News

Bayer HealthCare and Onyx Pharmaceuticals (Onyx) have initiated patient enrollment in an international phase III trial. The study is to evaluate Nexavar (sorafenib) tablets for the treatment of

Allergan has announced that the US District Court for the District of Delaware ruled in favor of Allergan in its patent infringement suit against Exela PharmSci, Exela PharmSci,

Cohera Medical (Cohera) has received approval to initiate human clinical trials of its lead product, TissuGlu, in Germany. Receipt of the approval allows Cohera Medical to proceed with

BioCryst has announced that the FDA, has issued an Emergency Use Authorisation (EUA) for the investigational anti-viral drug intravenous iv Peramivir in certain adult and pediatric patients with

Boehringer Ingelheim has reported that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Evaluation Agency (EMEA) has issued a positive opinion for the

Potentia Pharmaceuticals (Potentia) has entered into licensing and purchase option agreements with Alcon. The agreements provide Alcon with a license to develop Potentia’s leading drug candidate, POT-4, for

XETA Technologies has been selected by Siemens Enterprise Networks to provide technical support services for the US operations of a global pharmaceutical company. XETA provides services on behalf

Mediware Information Systems has announced that the Blood Bank of Alaska is the latest blood center to license LifeTrak, the company’s 510(k) cleared blood donor management software. Using

Fuji Health Science, a nutraceutical and pharmaceutical bulk ingredient company, has extended its F-Melt and Fujicalin for the dietary supplement industry. F-Melt is compressible and designed for oral